[{"address1": "Gooimeer 2-35", "city": "Naarden", "zip": "1411 DC", "country": "Netherlands", "phone": "31 35 206 2971", "website": "https://www.newamsterdampharma.com", "industry": "Biotechnology", "sector": "Healthcare", "longBusinessSummary": "NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases. The company also develops Obicetrapib which is in Phase 2a clinical trial for Alzheimer's disease. NewAmsterdam Pharma Company N.V. is headquartered in Naarden, the Netherlands.", "fullTimeEmployees": 29, "companyOfficers": [{"maxAge": 1, "name": "Dr. Michael Harvey Davidson FACC, Facp., M.D.", "age": 67, "title": "CEO, President, Executive Board Member & Director", "yearBorn": 1956, "fiscalYear": 2023, "totalPay": 885600, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Johannes Jacob Pieter Kastelein FESC, M.D., Ph.D.", "age": 69, "title": "Founder, Chief Scientific Officer, Member of Executive Board & Director", "yearBorn": 1954, "fiscalYear": 2023, "totalPay": 677758, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Mayur Amrat Somaiya", "age": 49, "title": "Chief Financial Officer", "yearBorn": 1974, "fiscalYear": 2023, "totalPay": 402304, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Juliette  Audet M.B.A., M.Sc.", "age": 36, "title": "Chief Business Officer", "yearBorn": 1987, "fiscalYear": 2023, "totalPay": 45625, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Douglas F. Kling", "age": 50, "title": "Chief Operating Officer", "yearBorn": 1973, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Louise  Kooij", "age": 47, "title": "Chief Accounting Officer", "yearBorn": 1976, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Matthew  Philippe", "title": "Executive VP &Head of Investor Relations", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Jim  Jacobson", "title": "Chief Legal Officer & Secretary", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Bob  Rambo", "title": "Executive Vice President of Marketing", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Marc  Ditmarsch M.D.", "age": 56, "title": "Chief Development Officer", "yearBorn": 1967, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}], "compensationAsOfEpochDate": 1703980800, "maxAge": 86400, "priceHint": 2, "previousClose": 12.64, "open": 13.23, "dayLow": 12.33, "dayHigh": 13.28, "regularMarketPreviousClose": 12.64, "regularMarketOpen": 13.23, "regularMarketDayLow": 12.33, "regularMarketDayHigh": 13.28, "volume": 18075, "regularMarketVolume": 18075, "averageVolume": 4153, "averageVolume10days": 11400, "averageDailyVolume10Day": 11400, "fiftyTwoWeekLow": 1.71, "fiftyTwoWeekHigh": 14.67, "fiftyDayAverage": 8.1032, "twoHundredDayAverage": 8.969695, "currency": "USD", "floatShares": 34819975, "bookValue": 4.097, "priceToBook": 3.151086, "netIncomeToCommon": -198916000, "exchange": "NGM", "quoteType": "EQUITY", "symbol": "NAMSW", "underlyingSymbol": "NAMSW", "shortName": "NewAmsterdam Pharma Company N.V", "longName": "NewAmsterdam Pharma Company N.V.", "firstTradeDateEpochUtc": 1612967400, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EST", "uuid": "072ede56-783e-317d-b7d9-5dc797a27eef", "gmtOffSetMilliseconds": -18000000, "currentPrice": 12.91, "recommendationKey": "none", "totalCash": 422728992, "totalCashPerShare": 4.571, "ebitda": -184059008, "totalDebt": 506000, "quickRatio": 10.247, "currentRatio": 10.614, "totalRevenue": 33594000, "debtToEquity": 0.134, "revenuePerShare": 0.373, "returnOnAssets": -0.29273, "returnOnEquity": -0.59622, "freeCashflow": -108734752, "operatingCashflow": -154156992, "revenueGrowth": 8.898, "grossMargins": 1.0, "operatingMargins": -0.85888, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2024-11-11"}]